LEXICON PHARMACEUTICALS, INC. Income Tax Expense
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Income Tax Expense of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-03-05
- LEXICON PHARMACEUTICALS, INC. income tax expense (benefit) for the quarter ending 2011-12-31 was $0.00.
- LEXICON PHARMACEUTICALS, INC. income tax expense (benefit) for the quarter ending 2011-09-30 was $0.00.
- LEXICON PHARMACEUTICALS, INC. income tax expense (benefit) for the quarter ending 2010-12-31 was $0.00.
- LEXICON PHARMACEUTICALS, INC. income tax expense (benefit) for the quarter ending 2010-09-30 was -$26.00K.
- LEXICON PHARMACEUTICALS, INC. income tax expense (benefit) for fiscal 2024 was $0.00.
- LEXICON PHARMACEUTICALS, INC. income tax expense (benefit) for fiscal 2023 was $0.00.
- LEXICON PHARMACEUTICALS, INC. income tax expense (benefit) for fiscal 2022 was $0.00.
- LEXICON PHARMACEUTICALS, INC. income tax expense (benefit) for fiscal 2021 was $0.00.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2026-03-05 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-05 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-07 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-25 | |||
| 2016-12-31 | $0.00 10-K · filed 2018-03-01 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-03-01 | |||
| 2014-12-31 | -$70.00K 10-K · filed 2017-03-06 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-03-11 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-12 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07 | $0.00 derived: sum of 2 quarters · filed 2014-03-07 | $0.00 10-K · filed 2014-03-07 | |
| 2011-09-30 | $0.00 10-Q · filed 2011-11-01 | $0.00 10-Q · filed 2011-11-01 | ||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | -$26.00K derived: sum of 2 quarters · filed 2013-03-11 | -$26.00K 10-K · filed 2013-03-11 | |
| 2010-09-30 | -$26.00K 10-Q · filed 2011-11-01 | -$26.00K 10-Q · filed 2011-11-01 | ||
| 2009-12-31 | -$102.00K 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |